Ziegler v. GW Pharmaceuticals, PLC

CourtDistrict Court, S.D. California
DecidedJanuary 18, 2022
Docket3:21-cv-01019
StatusUnknown

This text of Ziegler v. GW Pharmaceuticals, PLC (Ziegler v. GW Pharmaceuticals, PLC) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ziegler v. GW Pharmaceuticals, PLC, (S.D. Cal. 2022).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 KURT ZIEGLER, Case No. 21-cv-01019-BAS-MSB

12 Plaintiff, ORDER: 13 v. (1) APPOINTING LEAD 14 GW PHARMACEUTICALS, PLC, et al., PLAINTIFF; AND 15 Defendants. (2) APPROVING SELECTION OF 16 LEAD COUNSEL 17 (ECF No. 7) 18

19 20 21 22 23 24 This is a federal securities class action pertaining to allegedly false and misleading 25 statements made by Defendant GW Pharmaceuticals, PLC (“GW”), and its officers, 26 regarding a merger agreement between GW and Jazz Pharmaceuticals, PLC (“Jazz”), 27 which closed on May 5, 2021. Pending before the Court is a motion for appointment of 28 Lead Plaintiff and Lead Counsel in this litigation. (ECF No. 7.) For the reasons herein, 1 the Court appoints Kurt Ziegler and Daniel Brady as Lead Plaintiff and approves their 2 selection of Lead Counsel. 3 4 I. APPOINTMENT OF LEAD PLAINTIFF 5 Pursuant to the Private Securities Litigation Reform Act of 1995 (“PSLRA”), the 6 district court “shall appoint as lead plaintiff the member or members of the purported class 7 that the court determines to be the most capable of adequately representing the interest of 8 the class members[.]” 15 U.S.C. § 78u-4(a)(3)(B)(i). “[A] ‘group of persons’ can 9 collectively serve as a lead plaintiff.” In re Cavanaugh, 306 F.3d 726, 731 n.8 (9th Cir. 10 2002). The PSLRA creates a rebuttable presumption that the most adequate plaintiff 11 should be the plaintiff who: (1) has filed the complaint or brought the motion for 12 appointment of lead counsel in response to the publication of notice, (2) has the “largest 13 financial interest” in the relief sought by the class, and (3) otherwise satisfies the 14 requirements of Federal Rule of Civil Procedure 23. 15 U.S.C. § 78u- 15 4(a)(3)(B)(iii)(I)(aa)–(cc). The presumption may be rebutted only upon proof that the 16 presumptive lead plaintiff: (1) will not fairly and adequately protect the interests of the 17 class or (2) is subject to “unique defenses” that render such plaintiff incapable of adequately 18 representing the class. 15 U.S.C. § 78u-4(a)(3)(B)(iii)(II)(aa)–(bb). 19 By its terms, the PSLRA “provides a simple three-step process for identifying the 20 lead plaintiff” in a private securities class action litigation. In re Cavanaugh, 306 F.3d 726, 21 729 (9th Cir. 2002). “The first step consists of publicizing the pendency of the action, the 22 claims made and the purported class period.” Id. At the second step, “the district court 23 must consider the losses allegedly suffered by the various plaintiffs,” and select as the 24 “presumptively most adequate plaintiff . . . the one who has the largest financial interest in 25 the relief sought by the class and otherwise satisfies the requirements of Rule 23 of the 26 Federal Rules of Civil Procedure.” Id. at 729–30 (internal citations omitted). Finally, at 27 the third step, the district court “give[s] other plaintiffs an opportunity to rebut the 28 presumptive lead plaintiff’s showing that it satisfies Rule 23’s typicality and adequacy 1 requirements.” Id. at 730. The Court undertakes each of these steps for the consolidated 2 action. 3 4 A. Preliminary Procedural Requirements 5 Pursuant to the PSLRA, a plaintiff who files a securities litigation class action must 6 provide notice to class members via publication in a widely-circulated national business- 7 oriented publication or wire service within 20 days of filing the complaint. 15 U.S.C. 8 § 78u-4(a)(3)(A)(I). The notice must: (1) advise class members of the pendency of the 9 action, the claims asserted therein, and the purported class period; and (2) inform potential 10 class members that, within 60 days of the date on which notice was published, any members 11 of the purported class may move the court to serve as lead plaintiff in the purported class. 12 15 U.S.C. § 78u-4(a)(3)(A)(i)(I)–(II). 13 This action was filed in this District on May 27, 2021. (ECF No. 1.) Notice was 14 published in PRNewswire on June 4, 2021, by the law firm Monteverde & Associates PC. 15 (Bower Decl. Ex. A, ECF No. 7-1; Bower Decl. ¶ 2, ECF No. 7-8.) The notice was timely 16 published within 20 days after the filing of the complaint, it lists the claims and the class 17 period, and it advises putative class members that they had 60 days from the date of the 18 notice to file a motion to seek appointment as lead plaintiff in the lawsuit. See 15 U.S.C. 19 § 78u-4(a)(3)(A). Ziegler and Brady filed a motion for appointment as lead plaintiff within 20 the allotted period. Thus, notice in this action is proper and the movants have satisfied the 21 statutory procedural requirements for moving to be appointed as Lead Plaintiff. 22 23 B. Financial Interest 24 The PSLRA mandates that the district “court shall consider any motion made by a 25 purported class member in response to the notice . . . and shall appoint as lead plaintiff the 26 member or members of the purported plaintiff class that the court determines to be most 27 capable of adequately representing the interest of class members.” 15 U.S.C. § 78u- 28 4(a)(3)(B)(i). The PSLRA creates a presumption that the most capable plaintiff is the one 1 who “has filed the complaint or brought the motion for appointment of lead counsel in 2 response to the publication of notice” and “in the determination of the court, has the largest 3 financial interest in the relief sought by the class.” 15 U.S.C. § 78u-4(a)(3)(B)(iii)(I)(bb); 4 see also Inchen Huang v. Depomed, Inc., 289 F. Supp. 3d 1050, 1052 (N.D. Cal. 2017). In 5 practice, district courts “equate financial interest with actual economic losses suffered” or 6 “with potential recovery.” Perlmutter v. Intuitive Surgical, Inc., No. 10-cv-3451-LHK, 7 2011 WL 566814, at *3 (N.D. Cal. 2011) (citations omitted); see also Inchen Huang, 289 8 F. Supp. 3d at 1052 (“[A]pproximate losses in the subject securities is the preferred 9 measure.”) (quoting Bruce v. Suntech Power Holdings Co., No. CV 12-04061 RS, 2012 10 WL 5927985, at *2 (N.D. Cal. Nov. 13, 2012)). 11 Here, Ziegler is the one who has filed the Complaint, and Ziegler and Brady together 12 move for appointment of lead plaintiff and lead counsel. Ziegler submits that he held 100 13 American Depositary Shares (“ADS”) of GW before the merger, and Brady submits that 14 he held 250 ADS of GW during the relevant period. (Exs. B, C to Bower Decl., ECF Nos. 15 7-2, 7-3.) No one else has filed a competing motion for appointment of lead plaintiff. 16 Where, as here, the movants “are the sole parties seeking to be appointed as Lead 17 Plaintiffs,” they are “entitled to the presumption that [they hold] the largest financial 18 interest.” Siegall v. Tibco Software, Inc., No. C 05-2146 SBA, 2006 WL 1050173, at *4 19 (N.D. Cal. Feb. 24, 2006).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

The Town of Pawlet v. D. CLARK & OTHERS
13 U.S. 292 (Supreme Court, 1815)
Ellis v. Costco Wholesale Corp.
657 F.3d 970 (Ninth Circuit, 2011)
Cindy Castillo v. Bank of America, Na
980 F.3d 723 (Ninth Circuit, 2020)
Hanlon v. Chrysler Corp.
150 F.3d 1011 (Ninth Circuit, 1998)
Inchen Huang v. Depomed, Inc.
289 F. Supp. 3d 1050 (N.D. California, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
Ziegler v. GW Pharmaceuticals, PLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ziegler-v-gw-pharmaceuticals-plc-casd-2022.